Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amarin Corp Ads (AMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,970,717
  • Shares Outstanding, K 322,916
  • Annual Sales, $ 229,210 K
  • Annual Income, $ -116,450 K
  • 60-Month Beta 1.27
  • Price/Sales 25.91
  • Price/Cash Flow N/A
  • Price/Book 45.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.11
  • Number of Estimates 3
  • High Estimate -0.06
  • Low Estimate -0.15
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -37.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.65 +14.83%
on 03/27/19
20.97 -8.82%
on 04/01/19
+1.61 (+9.19%)
since 03/25/19
3-Month
15.65 +22.17%
on 02/07/19
23.25 -17.76%
on 03/05/19
+1.78 (+10.27%)
since 01/25/19
52-Week
2.35 +713.62%
on 07/31/18
23.33 -18.05%
on 11/06/18
+16.44 (+613.43%)
since 04/25/18

Most Recent Stories

More News
What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.

AMRN : 19.12 (+3.41%)
INCY : 73.94 (+0.57%)
GILD : 64.14 (+2.13%)
ADRO : 3.55 (-0.56%)
Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019

Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to...

AMRN : 19.12 (+3.41%)
CLASS ACTION DEADLINE for CAG and AMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

AMRN : 19.12 (+3.41%)
CAG : 30.95 (-1.05%)
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amarin Corporation plc ("Amarin" or "the Company")...

AMRN : 19.12 (+3.41%)
CLASS ACTION UPDATE for AMRN, SYNH, WSR and FSNN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

AMRN : 19.12 (+3.41%)
SYNH : 46.45 (-0.15%)
WSR : 12.46 (-0.64%)
FSNN : 0.1280 (-2.66%)
FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...

AMRN : 19.12 (+3.41%)
HIIQ : 24.55 (-0.81%)
AKRX : 2.99 (+2.75%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMRN, VNDA, WTW and APYX

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

APYX : 4.73 (+8.24%)
AMRN : 19.12 (+3.41%)
WTW : 19.07 (-2.41%)
VNDA : 16.62 (-1.19%)
APRIL 23 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Amarin Corporation plc - AMRN

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Amarin Corporation plc (NASDAQ: AMRN) from September 24, 2018 through November 9,...

AMRN : 19.12 (+3.41%)
Biotech Brief: Report Reveals Growing Global Demand for Non-Invasive Cellulite Treatment Options

Reports suggest that there is growing demand from consumers, especially those with disposable income, to look for non-herbal, non-invasive solutions to combat cellulite. Consumers are also now, more inclined,...

BHVN : 64.36 (+1.92%)
AMRN : 19.12 (+3.41%)
HLS.TO : 16.55 (unch)
MDT : 86.86 (+1.42%)
PFE : 39.61 (+0.61%)
SOLY : 11.75 (-4.70%)
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Amarin (AMRN) closed at $18.99, marking a +1.06% move from the previous day.

AMRN : 19.12 (+3.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade AMRN with:

Business Summary

Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.

See More

Key Turning Points

2nd Resistance Point 19.93
1st Resistance Point 19.53
Last Price 19.12
1st Support Level 18.40
2nd Support Level 17.67

See More

52-Week High 23.33
Last Price 19.12
Fibonacci 61.8% 15.32
Fibonacci 50% 12.84
Fibonacci 38.2% 10.36
52-Week Low 2.35

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar